Search

The bladder capacities of 75 patients with superficial bladder tumors were measured prior to and during monthly intravesical instillation therapy with adriamycin. When taken off therapy, a decrease in bladder capacity of more than 20% was observed in 18 of the patients. In 14 of the treated patients an increase in bladder capacity of more than 20% was observed. In patients with reduced bladder capacity when taken off therapy, there were no correlations between the degree of decreased bladder capacity and the number of instillations or the total instilled amount of adriamycin, indicating that the observed decrease in bladder capacity was caused by the underlying disease and not by the treatment per se.

Intravesical instillation of Adriamycin has successfully been used in the treatment of bladder tumours. The Adriamycin concentration in the bladder has been monitored and the area under the bladder concentration-time curve, AUC, is proposed to be considered rather than the amount of instilled drug when optimizing the treatment schedules. pH effects which may arise in the bladder when instilling protolytic drugs like Adriamycin are discussed.

22 patients with Peyronie's disease have been treated with Orgotein, the new anti-inflammatory metalloprotein which pronounced superoxide dismutase activity patients with long-standing and severe symptoms were selected for the trial. The drug was given monthly by injection into the indurated areas of penis. In 19 patients, where the sexual act could be performed with difficulties or the penile angulation made intercourse impossible, marked improvement was seen or normal function was restored. No adverse reactions by Orgotein were seen.